Cited by 273Inflammasome and immune disordersAcute Myeloid Leukemia ResearchBlood disorders and treatments

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Open access

Sallman, David A., List, Alan·2019·Blood

DOI 10.1182/blood-2018-10-844654PMC PMC7022316

Open this paper in CoChat — free account Open PDF

Abstract

In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment play a vital role in disease pathogenesis. In the past decade, aberrant innate immune activation and proinflammatory signaling within the malignant clone and the bone marrow (BM) microenvironment were identified as key pathogenic drivers of myelodysplastic syndromes (MDS). In particular, S100A9-mediated NOD-like receptor protein 3 (NLRP3) inflammasome activation directs an inflammatory, lytic form of cell death termed pyroptosis that underlies many of the hallmark features of the disease. This circuit and accompanying release of other danger-associated molecular patterns expands BM myeloid-derived suppressor cells, creating a feed-forward process propagating inflammasome activation. Furthermore, somatic gene mutations of varied functional classes license the NLRP3 inflammasome to generate a common phenotype with excess reactive oxygen species generation, Wnt/β-catenin-induced proliferation, cation flux-induced cell swelling, and caspase-1 activation. Recent investigations have shown that activation of the NLRP3 inflammasome complex has more broad-reaching importance, particularly as a possible disease-specific biomarker for MDS, and, mechanistically, as a driver of cardiovascular morbidity/mortality in individuals with age-related, clonal hematopoiesis. Recognition of the mechanistic role of aberrant innate immune activation in MDS provides a new perspective for therapeutic development that could usher in a novel class of disease-modifying agents.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2018-10-844654

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Pyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,288
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202

Show all 81 references

Sorted by citations

Items 201–273 of 273

MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C.-X., Gong, M., & Li, Z. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02913-3 · Cited by 2
Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation
Oster, H. S., Sklyar, E., Golsdshmidt, N., & Mittelman, M. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.044 · Cited by 2
Metchnikoff’s legacy: the dysplastic nature of innate immunity in myelodysplastic syndromes
Greenberg, P. L. (2021) · Haematologica · doi:10.3324/haematol.2021.279419 · Cited by 1
Identification and integrative analysis of microRNAs in myelodysplastic syndromes based on microRNAs expression profile
Ma, L., Yang, H., & Yang, X. (2021) · Precision Medical Sciences · doi:10.1002/prm2.12054 · Cited by 1
Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms
Weidner, H., Baschant, U., Ledesma-Colunga, M. G., Basiak, K., Tsourdi, E. A., Sockel, K., Götze, K. S. S., Rivière, J., Platzbecker, U., Hofbauer, L. C., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02315-6 · Cited by 1
Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes
Hong, M., Guo, J., Zhao, Y., Song, L., Zhao, S., Wang, R., Shi, L., Zhang, Z., Wu, D., He, Q., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177086 · Cited by 1
Prognostic Value of Inflammation and Nutrition-Based Scores in Low-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study
Ersal, T., Özkocaman, V., Çubukçu, S., Koca, T. G., Hunutlu, F. Ç., Yavuz, Ş., Elgün, E., Ocakoğlu, G., & Özkalemkaş, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134751 · Cited by 1
Impact of inflammatory cytokine polymorphisms on the progression of myelodysplastic syndromes
Gotoh, N., Munkh-Erdene, T., Hayashi, A., Kasamatsu, T., Kitamura, M., Kojima, A., Okawa, T., Oda, T., Miyauchi, E., Sasaki, N., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06614-5 · Cited by 1
Impact of iron chelation therapy on mitochondrial function, vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes
García‐Delgado, R., Moreno‐Carrasco, G., Carrasco-Gomariz, M., García-Segovia, S., Flores, R. M. O., Torres-González, J., Gallego-Fuillerat, G., López-Villodres, J. A., & Escamilla, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1683941 · Cited by 1
The role of macrophages and cytokines in the occurrence and development of MDS
Li, P. J., Li, S., Guan, D., Xu, W., Bian, J., Deng, J., Wang, H., & Ren, F. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02106-6 · Cited by 1
Pharmacologic progress in higher-risk MDS: an uphill battle
Mina, A. A., & Zeidan, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2644384 · Cited by 1
Inflammatory signatures in the spectrum of myeloid diseases
Ibbotson, A., Crouch, S., Ferrari, J., Young, T., Morgan, A. W., Gallì, A., Pozzi, S., Sarchi, M., Camilotto, V., Boldini, M., et al. (2026) · HemaSphere · doi:10.1002/hem3.70428 · Cited by 1
Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study
Soltani, M., Sharifi, M. J., Khalilian, P., Sharifi, M., Nematollahi, P., Shapourian, H., & Ganjalıkhani-Hakemi, M. (2024) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v18i2.15371 · Cited by 1
Assessing the associations of blood metabolites with myelodysplastic syndrome: A bidirectional mendelian randomization study
Hu, K., Cheng, Y., Xiao, G., Shen, X. Y., & Qian, S. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107723 · Cited by 1
Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy
Alary, A., Vignon, M., Carapito, R., Halabi, N. M., Willems, L., Green, A. S., Chapuis, N., Heshmati, F., Cuccuini, W., Kaltenbach, S., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1804562 · Cited by 1
Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?
Mariani, M., Mattiucci, D., Rossi, E., Mari, V., Masala, E., Giuliani, A., Santini, V., Olivieri, F., Busilacchi, E. M., Mancini, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595838 · Cited by 1
Myelodysplasia-associated Sweet’s syndrome: clinical and laboratory presentation and response to thalidomide
Wawrzycki, B., Jawniak, D., Pietrzak, A., Szumiło, J., & Krasowska, D. (2021) · Acta Haematologica Polonica · doi:10.5603/ahp.2021.0020 · Cited by 1
MDS Mimics Including CHIP, ICUS, and CCUS
Bejar, R. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_6
MDS Stem Cell Biology
Villaume, M. T., Ferrell, P. B., & Savona, M. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_4 · Cited by 1
Novel Therapeutic Strategies in Development for Myelodysplastic Syndromes
Hamed, N. A. M. (2019) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2019.13.555874
The Bone Marrow Microenvironment in Myelodysplastic Syndromes
Calvi, L. M., & Liesveld, J. L. (2019) · The Hematologist
Necrotizing myopathy associated with TET2-mutated myelodysplastic syndrome
Dietrich, T., de Mornac, D., Garnier, A., Espitia-Thibault, A., Néel, A., Normand, A., Toquet, C. S., & Agard, C. (2022) · QJM · doi:10.1093/qjmed/hcac144
Somatic mutations show no clear association with red blood cell or human leukocyte antigen alloimmunization in de novo or therapy‐related myelodysplastic syndrome
Adkins, B. D., Mehta, A., Selesky, M., Vittitow, S. L., Smolkin, M. E., Ratcliffe, S. J., & Luckey, C. J. (2022) · Transfusion · doi:10.1111/trf.17155
Multiparameter Flow Cytometry: An Important Auxiliary Tool for The Diagnosis and Differential Diagnosis of Myelodysplastic Neoplasms
Siqi, L., Rong, H., & Lou, S. (2023) · Diseases & Research · doi:10.54457/dr.202301005
The Role and Research Progress of NLRP3 Inflammasome and MDSC in Myelodysplastic Syndrome
张, 晓. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133564
Data from Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes
Aoyagi, Y., Hayashi, Y., Harada, Y., Choi, K., Matsunuma, N., Sadato, D., Maemoto, Y., Ito, A., Yanagi, S., Starczynowski, D. T., et al. (2023) · doi:10.1158/2159-8290.c.6549430.v1
Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients
Oran, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00018-8
Refining the Diagnosis and Treatment of Myelodysplastic Syndromes
Duetz, C. (2023) · doi:10.5463/thesis.397
Identification and validation of pyroptosis patterns in AML via comprehensive bioinformatics analysisPreprint
Zhang, H., Deng, Z., Huang, Z., Wang, P., Cheng, Z., & Peng, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3600674/v1
Clinical Challenges of Emerging Acquired Autoinflammatory Diseases, Including VEXAS Syndrome
Kirino, Y. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3219-23
Additional file 8 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C.-X., Gong, M., & Li, Z. (2021) · Figshare · doi:10.6084/m9.figshare.14707894
Myelodysplastic Neoplasms: The Impact of Clonality on Inflammatory-Degenerative Diseases of the Elderly
Bonadies, N. (2024) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2024.19.136
HMGA2 promotes platelet-neutrophil complex formation and pulmonary tissue damage in myelodysplastic syndromes
Matsunuma, N., Hayashi, Y., Fukuda, M., Yuki, K., Kamimura-Aoyagi, Y., Kobayashi, H., Shingai, N., Harada, Y., & Harada, H. (2024) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2024.100014
The Role of Inflammation and Nutrition-Based Scoring in Low-Risk Myelodysplastic SyndromePreprint
Ersal, T., Özkocaman, V., Çubukçu, S., Koca, T. G., Hunutlu, F. Ç., Yavuz, Ş., Elgün, E., & Özkalemkaş, F. (2024) · Research Square · doi:10.21203/rs.3.rs-4991051/v1
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes
Herrera, D. A., & Strumlowska, A. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00750-5
Identification and validation of pyroptosis patterns in AML via comprehensive bioinformatics analysis
Deng, Z., Zhu, H., Cheng, Z., Li, R., & Peng, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-02298-5
A Case of High-Risk Myelodysplastic Syndrome With Cryoglobulinemia, Hemophagocytic Lymphohistiocytosis, and Progression to Multiple Organ Failure
Kranjac, C. A., Hobbs, L. M., Feustel, K., & Carlson, K.-S. (2025) · Journal of Medical Cases · doi:10.14740/jmc5134
The NLRP3 inflammasome and its role in acute myeloid leukemia onset and development
Macedo, B., de Melo, M. A., Pereira‐Martins, D. A., Machado‐Neto, J. A., & Traina, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189371
Human IRAK kinases differentially alter metabolic regulation and mitochondrial function in Saccharomyces cerevisiaePreprint
del Val, E., Genna, G., Fernández‐Acero, T., Molina, M., & Cid, V. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.06.668917
Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes
Hong, J. (2025) · Blood Research · doi:10.1007/s44313-025-00099-x
Setd2 ensures the establishment of a precise basal inflammatory state within murine hematopoietic stem/progenitor cells
Tao, H., Luo, X., Song, J., Wang, F., Xie, Y., Fan, R., Sun, X., Huang, Q., & Zhang, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08110-0
Additional file 1 of Cigarette smoke impairs the hematopoietic supportive property of mesenchymal stem cells via the production of reactive oxygen species and NLRP3 activation
Park, H. S., Lee, B.-C., Chae, D.-H., Yu, A., Park, J. H., Heo, J., Han, M. H., Cho, K., Lee, J. W., Jung, J.-W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25857531
Additional file 5 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707885
Additional file 1 of TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes
Iriani, A., Rachman, A., Setiabudy, R. D., Kresno, S. B., Sudoyo, A. W., Arief, M., Harahap, A. R., & Fatina, M. K. (2023) · Figshare · doi:10.6084/m9.figshare.24603510
Additional file 2 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707876
Additional file 4 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C.-X., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707882
Additional file 7 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707891
Additional file 1 of Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia
Qiao, W., Young, E. J., Feng, C., Liu, S., Jin, J., Noor, L., Rojas Hernandez, C. M., Borthakur, G., Gorlova, O. Y., & Afshar‐Kharghan, V. (2022) · Figshare · doi:10.6084/m9.figshare.21152764
Additional file 6 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707888
Additional file 1 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707873
Additional file 3 of MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Guo, C., Gao, Y.-Y., Ju, Q., Wang, M., Zhang, C., Gong, M., & Li, Z.-L. (2021) · Figshare · doi:10.6084/m9.figshare.14707879
Additional file 2 of Cigarette smoke impairs the hematopoietic supportive property of mesenchymal stem cells via the production of reactive oxygen species and NLRP3 activation
Park, H. S., Lee, B.-C., Chae, D.-H., Yu, A., Park, J. H., Heo, J., Han, M. H., Cho, K., Lee, J. W., Jung, J.-W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25857607
Additional file 1 of Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα
Oppezzo, A., Monney, L., Kilian, H., Slimani, L., Maczkowiak, F., & Rosselli, F. (2023) · Figshare · doi:10.6084/m9.figshare.23575396
Aberrant Kupffer-like differentiation of hematopoietic stem cell is critical for the MDS pathogenesis in Setd2-deficient mice
Song, J., Wang, F., Xie, Y., Luo, X., Tao, H., Fan, R., Zhou, Y., Wu, J., Huang, T., Zhao, H., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01715-8
Epigenetic control of S100A8/A9-driven monocytic inflammation licenses anti-leukemic functionality of immature NK cells during hematopoietic stem cell differentiationPreprint
Schirrmann, R. L., Stowitschek, D., Sutter, M. F., Lee, J.-H., Zhao, B., Lee, S., Neyazi, A., Broesamle, B. F., Ginsberg, F., Krammer, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.25.714180
Rôle des protéines NLRP dans la physiopathologie des membranes foetales humaines.
Lavergne, M. (2019) · theses.fr (ABES) · doi:10.70675/cba6093az04b5z4414zb6a6z98dbbf90ced1
High resolution characterization of human erythroid progenitor’s heterogeneity : implications for understanding physiological and pathological erythropoiesis.
Yan, H. (2021) · theses.fr (ABES) · doi:10.70675/3e8c2fabz0ab9z40efz8152ze9f855af54b0
Cellular and molecular characterization of hematopoietic stem cells and bone marrow niche abnormalities in Fanconi anemiaCaractérisation cellulaire et moléculaire des anomalies des cellules souches hématopoïétiques et de leur niche dans l’anémie de Fanconi
Oppezzo, A. (2021) · theses.fr (ABES) · doi:10.70675/53736911zeb54z418czb336z493f788bd19f
Stromal Gasdermin D-mediated Pyroptosis Drives Maladaptive CD4⁺ T-cell Remodeling in Tet2-Deficient HematopoiesisPreprint
Ren, K., Han, X., Li, E., Wang, P., Bi, H., Cai, W., Aydemir, I., Wai, C. M., Niu, H., Yang, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.01.722102
Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia
Tripathi, C., Luh, F., & Yen, Y. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201217
Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M Analysis
Jeong, D. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.010
Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice
Vilcassim, S., Pholngam, N., Thubthed, R., Nualkaew, T., Svasti, S., Chaichompoo, P., Kysenius, K., Crouch, P. J., Dames, S., Eisermann, M., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70391
Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenvironment, and Therapy
Bottaro, A., Nasso, M. E., Mirabile, G., Fazio, M., & Allegra, A. (2026) · Cells · doi:10.3390/cells15131137
Neutrophil-Derived S100A8/A9 Drives Inflammation that Promotes Dnmt3a -Mutant HematopoiesisPreprint
Mistry, J. J., Fournier, N. R., Nye, G. J., & Trowbridge, J. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.26.734778
A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML
Brunner, A. M., Liu, Y., Garcia, J. S., Mendez, L., Gutierrez, C., Srivatsan, S. N., Shao, J., Aubrey, B. J., Amrein, P. C., Narayan, R., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019848
Non-invasive differentiation between aplastic anemia and myelodysplastic syndromes based on an 8-feature lightGBM model: A multicenter external validation study
Wang, S., Cai, Z., Wei, W., Zhang, S., Chen, S., & Zhang, Y. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103602
PANoptosis in the pathogenesis of myelodysplastic syndromes
Thalla, R., Lamichhane, J., Lewis, C., Breslin, P., & Zhang, J. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70309
T lymphocytes and natural killer cells in myelodysplastic syndromes: function, dysfunction, and therapeutic potential
Cheng, J., Tam, E. L., & O'Connell, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1907953
Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials
Kubasch, A. S., Zoldan, K., Brauer, D., Kiewe, P. M., Sasca, D., Sockel, K., Illmer, T., Giagounidis, A. A. N., Nowak, D., Rieger, K., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01885-z
Lung-Predominant Hyperinflammatory Syndrome in Therapy-Related Myelodysplastic Syndrome Responsive to Interleukin-1 Blockade
Smith, Q. C., & Arar-Cauley, A. (2026) · Hematology Reports · doi:10.3390/hematolrep18050068
Prognostic Value of Peripheral Blood Inflammatory Markers and Blast Percentage in Myelodysplastic Syndromes: A Systematic Review and Meta‐Analysis
Berta, D. M., Walle, M., Wolde, G., Cherie, N., & Lin, C. (2026) · Mediators of Inflammation · doi:10.1155/mi/7508593
Inflammasome activation promotes the progression of myelodysplastic syndrome
Andoh, S., Nakajima‐Takagi, Y., Uemura, S., Atsuta, Y., Fukuta, T., Miyota, M., Saiki-Tsuchiya, A., Koide, S., Oshima, M., Rahmutulla, B., et al. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105960
Frequency and Potential Disease-Modifying Role of MEFV Variants in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Case–Control Study
Işık, Ö., Eren, F., Yanık, A. M., Arıkan, F., Yılmaz, A. F., Toptaş, T., Atagündüz, M. P., Karadağ, D. Y., & Atagündüz, I. (2026) · Medicina · doi:10.3390/medicina62112093

Authors: Sallman, D. A., & List, A.
Affiliations: Moffitt Cancer Center (US)
ORCID: Sallman, David A.
List, Alan
Venue: Blood
Publisher: American Society of Hematology
Published: 2019-03-07
Volume: 133
Issue: 10
Pages: 1039-1048
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2018-10-844654
PMC: PMC7022316
OpenAlex: W2913296480
Cited by: 273
References: 81
Citations by year: 2026: 26 · 2025: 27 · 2024: 39 · 2023: 47 · 2022: 38 · 2021: 59 · 2020: 23 · 2019: 14
FWCI: 2.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA076292)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Hematology › Blood disorders and treatments
Keywords: myelodysplastic syndrome, NLRP3 inflammasome, S100A9, pyroptosis, bone marrow microenvironment, myeloid-derived suppressor cells, innate immune activation, clonal hematopoiesis, cardiovascular morbidity, caspase-1, reactive oxygen species, Wnt/β-catenin signaling, disease biomarkers, disease-modifying therapy
MeSH terms: Pyroptosis, NLR Family, Pyrin Domain-Containing 3 Protein, Bone Marrow, Bone Marrow Cells, Hematopoiesis, Humans, Immunity, Innate, Inflammation, Mutation, Myelodysplastic Syndromes, Phenotype, Signal Transduction, Reactive Oxygen Species, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks